This is a preview of subscription content, log in via an institution to check access.
REFERENCES
D. J. Greenblatt, R. I. Shader, K. Franke, D. S. MacLaughlin, J. S. Harmatz, M. D. Allen, A. Werner, and E. Woo. Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans. J. Pharm. Sci. 68:57–63 (1979).
C. D. Klassen, D. L. Eaton, and S. Z. Cagen. Hepatobiliary disposition of xenobiotics. In J. W. Bridges and L. F. Chasseaud (eds.), Progress in Drug Metabolism, Vol. 6, John Wiley and Sons, New York, 1981, pp. 27–28.
W. G. Levine. Biliary excretion of drugs and other xenobiotics. Annu. Rev. Pharmacol. Toxicol. 18:81–96 (1978).
D. J. Greenblatt and L. R. Engelking. Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. J. Pharmacol. Exp. Ther. 244:674–679 (1988).
R. J. Herman, J. D. Van Pham, and C. B. N. Szakacs. Disposition of lorazepam in human beings: Enterohepatic recirculation and first-pass effect. Clin. Pharmacol. Ther. 46:18–25 (1989).
T. Meinertz, H. J. Gilfrich, U. Groth, H. G. Jonen, and E. Jahnchen. Interruption of the enterohepatic circulation of phenprocouman by cholestyramine. Clin. Pharmacol. Ther. 21:731–735 (1977).
J. H. Caldwell, C. A. Bush, and N. J. Greenberger. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. J. Clin. Invest. 50:2638–2644 (1971).
T. W. Guentert, M. Schmitt, and R. Defoin. Acceleration of the elimination of tenoxicam by cholestyramine. J. Pharmacol. Exp. Ther. 238:295–301 (1986).
V. W. Payne, R. A. Secter, and R. K. Noback. Use of colestipol in a patient with digoxin intoxication. Drug Intell. Clin. Pharm. 15:902–903 (1981).
H. Ko and M. E. Royer. In vitro binding of drugs to colestipol hydrochloride. J. Pharm. Sci. 63:1914–1920 (1974).
Y. Arabi, F. Dimock, D. W. Burdon, J. Alexander-Williams, and M. R. B. Keighley. Influence of metronidazole and neomycin on colonic microflora in healthy volunteers. Gut 18:A969 (1977).
J. E. F. Reynolds. Martindale, The Extra Pharmacopoeia, 29th ed., Pharmaceutical Press, London, 1989, pp. 1197–1198.
D. G. Gallo, K. R. Bailey, and A. L. Sheffner. The interaction between cholestyramine and drugs. Proc. Soc. Exp. Biol. Med. 120:60–65 (1965).
W. G. Karr, W. O. Abbott, and A. B. Sample. Intubation studies of human small intestine; Chemical characteristics of intestinal contents in fasting state and as influenced by administration of acids, of alkalis and of water. J. Clin. Invest. 14:893–900 (1935).
B. Borgstrom, A. Dahlquist, G. Lundh, and J. Sjovall. Studies of intestinal digestion and absorption in the human. J. Clin. Invest. 36:1521–1536 (1957).
Z. H. Israili and P. G. Dayton. Enhancement of xenobiotic elimination: Role of intestinal excretion. Drug Metab. Rev. 15:1123–1159 (1984).
G. Levy. Gastrointestinal clearance of drugs with activated charcoal. N. Engl. J. Med. 307:676–678 (1982).
W. J. Cady, T. L. Rehder, and J. Campbell. Use of cholestyramine resin in the treatment of digitoxin toxicity. Am. J. Hosp. Pharm. 36:92–94 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herman, R.J., Chaudhary, A. In Vitro Binding of Lorazepam and Lorazepam Glucuronide to Cholestyramine, Colestipol, and Activated Charcoal. Pharm Res 8, 538–540 (1991). https://doi.org/10.1023/A:1015823816776
Issue Date:
DOI: https://doi.org/10.1023/A:1015823816776